Document Detail

MedLine Citation:
PMID:  16541185     Owner:  NLM     Status:  MEDLINE    
New therapies, in particular the tumor necrosis factor-alpha-blocking drugs, have led to improved control of inflammation in rheumatoid arthritis for a proportion of patients. There remains a need for therapies for patients who do not respond to these drugs or in whom they are contraindicated or not tolerated. There is evidence that T cells are involved in the initiation and perpetuation of rheumatoid arthritis. Abatacept is the first in a new class of drugs targeted at T-cell function in autoimmune disease: the costimulation blockers. It has shown safety and efficacy in rheumatoid arthritis. Further trials of this and other costimulation blockers are in progress in rheumatoid arthritis and other diseases.
Edward M Vital; Paul Emery
Related Documents :
3503915 - The evaluation of therapeutic efficacy of hachimi-jio-gan (traditional chinese medicine...
20831715 - Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid ...
12426295 - Lung injury linked to etanercept therapy.
6719065 - Thiopronine-induced pemphigus vulgaris in rheumatoid arthritis.
7984835 - Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurologic...
12120985 - In vitro effect of nitazoxanide against entamoeba histolytica, giardia intestinalis and...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  42     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-03-16     Completed Date:  2006-05-12     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  87-93     Citation Subset:  IM    
Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents* / adverse effects,  pharmacology,  therapeutic use
Arthritis, Rheumatoid / drug therapy*,  immunology
Clinical Trials as Topic
Immunoconjugates* / adverse effects,  pharmacology,  therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  immunology
Reg. No./Substance:
0/Antirheumatic Agents; 0/Immunoconjugates; 0/Tumor Necrosis Factor-alpha; 7D0YB67S97/abatacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dronedarone: a new antiarrhythmic agent.
Next Document:  Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.